NCT07409350

Brief Summary

This study includes finalization of the LINKED social network intervention to improve PrEP and MOUD uptake among people who inject drugs (PWID) in collaboration with an Expert Advisory Board and staff (N=16) at The Sidewalk Project (TSP), followed by a Hybrid Type II cluster randomized trial of the LINKED intervention (versus an equal-attention control) among N=372 people who inject drugs, with 6- and 12-month follow-up assessment of PrEP and MOUD uptake. The investigators will also evaluate implementation outcomes to inform future sustainable implementation of LINKED in harm reduction organizations.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
398

participants targeted

Target at P75+ for not_applicable

Timeline
23mo left

Started Jan 2027

Typical duration for not_applicable

Geographic Reach
1 country

3 active sites

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 9, 2026

Completed
4 days until next milestone

First Posted

Study publicly available on registry

February 13, 2026

Completed
11 months until next milestone

Study Start

First participant enrolled

January 1, 2027

Expected
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2028

Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2028

Last Updated

February 13, 2026

Status Verified

February 1, 2026

Enrollment Period

1.9 years

First QC Date

February 9, 2026

Last Update Submit

February 9, 2026

Conditions

Outcome Measures

Primary Outcomes (8)

  • Percentage of Participants with PrEP Uptake

    Measured via filled PrEP prescription.

    Month 6

  • Percentage of Participants with PrEP Uptake

    Measured via filled PrEP prescription.

    Month 12

  • Percentage of Participants with MOUD Uptake

    Measured via filled MOUD prescription or buprenorphine, methadone, or naltrexone enrollment.

    Month 6

  • Percentage of Participants with MOUD Uptake

    Measured via filled MOUD prescription or buprenorphine, methadone, or naltrexone enrollment.

    Month 12

  • Percentage of Participants with PrEP Adherence

    Measured via urine immunoassays to test for oral PrEP.

    Month 6

  • Percentage of Participants with PrEP Adherence

    Measured via urine immunoassays to test for oral PrEP.

    Month 12

  • Percentage of Participants with MOUD Adherence

    Measured via urinalysis to test for metabolites for MOUD.

    Month 6

  • Percentage of Participants with MOUD Adherence

    Measured via urinalysis to test for metabolites for MOUD.

    Month 12

Study Arms (2)

LINKED Intervention

EXPERIMENTAL

Participants randomized to the LINKED arm will receive a peer change agent intervention consisting of a 3-hour workshop divided into four learning and practice modules.

Behavioral: LINKED

Equal-Attention Control

ACTIVE COMPARATOR

Participants randomized to the equal attention control group will receive a group intervention facilitated by trained study staff.

Behavioral: Group Intervention

Interventions

LINKEDBEHAVIORAL

LINKED is a theory-driven social network intervention (SNI) that leverages peer influence within the social networks of people who inject drugs (PWID) to disseminate information, encourage communication, and increase pre-exposure prophylaxis (PrEP) and medications for opioid use disorder (MOUD) uptake and persistence in harm reduction organization (HRO) settings.

LINKED Intervention

Group intervention facilitated by trained study staff that supports critical thinking about what constitutes low, medium, and high risks for HIV and overdose.

Equal-Attention Control

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Aim 1 - Virtual Focus Group
  • Is 18 years or older
  • Is a current TSP staff
  • Is capable and willing to provide consent
  • Aim 2 - Intervention
  • years or older
  • Spend majority of their time in the Los Angeles, CA area where recruited
  • Able to complete surveys and group sessions in English
  • Self-report to have injected drugs in the past 3 months
  • Self-reported HIV negative serostatus
  • Not currently on PrEP or MOUD
  • Not pregnant
  • If a network recruit: presents a valid recruitment coupon
  • Is capable and willing to provide consent
  • Aim 3 - Virtual Focus Group/Surveys
  • +3 more criteria

You may not qualify if:

  • Aims 1 and 3:
  • Individuals who are not current TSP staff members will be excluded from participation.
  • Aim 2:
  • Under age 18;
  • Does not spend majority of time in the Los Angeles, CA area where recruited;
  • Unable to complete surveys and groups sessions in English;
  • Does not self-report injecting drugs in past 3 months;
  • Self-reported HIV positive serostatus
  • Currently on PrEP or MOUD
  • Currently pregnant
  • If a network recruit: does not present a valid recruitment coupon

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

University of Southern California

Los Angeles, California, 90033, United States

Location

The University of Chicago

Chicago, Illinois, 60637, United States

Location

NYU Langone Health

New York, New York, 10016, United States

Location

MeSH Terms

Conditions

Substance-Related Disorders

Condition Hierarchy (Ancestors)

Chemically-Induced DisordersMental Disorders

Study Officials

  • Suzan Walters, PhD

    NYU Langone Health

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 9, 2026

First Posted

February 13, 2026

Study Start (Estimated)

January 1, 2027

Primary Completion (Estimated)

December 1, 2028

Study Completion (Estimated)

December 1, 2028

Last Updated

February 13, 2026

Record last verified: 2026-02

Data Sharing

IPD Sharing
Will share

The de-identified participant data from the final research dataset will be shared upon reasonable request beginning 9 to 36 months after publication or as required by a condition of awards or supporting agreements, provided the requesting investigator executes a data use agreement with NYU Langone Health. This instance of data sharing will also require separate IRB review as well as review from NYU Langone's Data Sharing Strategy Board (DSSB). Requests should be directed to: Suzan.Walters@nyulangone.org. The protocol and statistical analysis plan will be posted on Clinicaltrials.gov only as required by federal regulation or supporting awards and agreements.

Shared Documents
STUDY PROTOCOL, SAP, ICF
Time Frame
Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.
Access Criteria
The investigator who proposed to use the data will be granted access upon reasonable request. Requests should be directed to Suzan.Walters@nyulangone.org. To gain access, data requestors will need to sign a data access agreement. This instance of data sharing will also require separate IRB review as well as review from NYU Langone's DSSB.

Locations